Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Drug Category : Array
Conference Category : Array
Lead Author : Cheah C, et al.
Published Date : 09/12/2019
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/12/ASH2019CCheahU2B.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top